Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Sigmund who wrote (733)	12/19/1997 2:02:00 PM
From: Sigmund	Respond to of 1894

I think the reference to Cytec's response to the Populist Cytologist cytopathnet.org was originally posted on the ACMI SI thread by Cisco. The data analysis presented on the Populist Cytologist's Internet site certainly did provide some cause for concern which I think will complicate the work of the FDA as they need to be extra sure they are doing the right thing, but I assume that the case for Thin Prep will eventually gain acceptance....as is being demonstrated by Cytec's progress in gaining reimbursement approval.

To: Sigmund who wrote (733)	12/23/1997 4:49:00 AM
From: Steven Zimmer	Read Replies (1) \| Respond to of 1894

Hi Sigmund May I suggest that I have also heard from other sources that the Cytc ThinPrep is not what is cracked up to be. There may be some studies emerging from a prominent French Laboratory that ThinPrep advantages are not sufficient to justify the cost. However, as far as ACMI is concerned, whether ThinPrep works or not is irrelevent as they have been able to show that their instrument has a significant impact on Cytopath lab productivity and, hence, profitability. If ThinPrep is what it is cracked up to be, all the better given the data that ACMI has generated. I have met with Gombrich recently and he is extremely upbeat about the company. So much so that he claims to be buying the stock at these prices! Greetings